D. Parry

发表

Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor

E. Lees, T. Fischmann, P. Kirschmeier, 2010, Molecular Cancer Therapeutics.

Cyclin D-CDK Subunit Arrangement Is Dependent on the Availability of Competing INK4 and p21 Class Inhibitors

E. Lees, K. Wills, D. Parry, 1999, Molecular and Cellular Biology.

Raf-induced proliferation or cell cycle arrest is determined by the level of Raf activity with arrest mediated by p21Cip1

E. Lees, D. Woods, M. McMahon, 1997, Molecular and cellular biology.

Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16

J. Bartek, J. Lukas, G. Peters, 1995, Nature.

Chk1 is Essential for Tumor Cell Viability Following Activation of the Replication Checkpoint

D. Parry, Song H. Cho, C. D. Toouli, 2005, Cell cycle.

Absence of cyclin D/cdk complexes in cells lacking functional retinoblastoma protein.

L. Bonetta, G. Peters, K. Vousden, 1994, Oncogene.

Active cdk6 complexes are predominantly nuclear and represent only a minority of the cdk6 in T cells

E. Lees, D. Parry, D. Mahony, 1998, Oncogene.

Discovery of Dinaciclib (SCH 727965): A Potent and Selective Inhibitor of Cyclin-Dependent Kinases.

E. Lees, T. Fischmann, P. Kirschmeier, 2010, ACS medicinal chemistry letters.

senescence . implications for cell immortalization and Regulation of p 16 CDKN 2 expression and its

G. Peters, E. Hara, D. Parry, 1996 .

Cyclin D2 is essential for BCR-mediated proliferation and CD5 B cell development.

Wei Wei Wu, R. Weinberg, E. Lam, 2000, International immunology.

Temperature-sensitive mutants of p16CDKN2 associated with familial melanoma

G. Peters, D. Parry, D. Parry, 1996, Molecular and cellular biology.

Discovery of pyrazolo[1,5-a]pyrimidine-based CHK1 inhibitors: a template-based approach--part 1.

T. Fischmann, W. Seghezzi, D. Parry, 2011, Bioorganic & medicinal chemistry letters.

Phase I and Pharmacologic Trial of Cytosine Arabinoside with the Selective Checkpoint 1 Inhibitor Sch 900776 in Refractory Acute Leukemias

M. McDevitt, K. Flatten, B. Smith, 2012, Clinical Cancer Research.

Versatile templates for the development of novel kinase inhibitors: Discovery of novel CDK inhibitors.

E. Lees, T. Fischmann, W. Seghezzi, 2007, Bioorganic & medicinal chemistry letters.

Loss of Integrin-Linked Kinase Sensitizes Breast Cancer to SRC Inhibitors

V. Brunton, D. Parry, A. Byron, 2021, Cancer research.

Phenotypic enhancement of thymidylate synthetase pathway inhibitors following ablation of Neil1 DNA glycosylase/lyase

R. Pierce, F. Shanahan, D. Parry, 2010, Cell cycle.

Accumulation of p16INK4a in mouse fibroblasts as a function of replicative senescence and not of retinoblastoma gene status

G. Peters, S. Bates, E. Hara, 1997, Oncogene.

A Functional Approach Reveals a Genetic and Physical Interaction between Ribonucleotide Reductase and CHK1 in Mammalian Cells

F. Shanahan, D. Parry, L. Taricani, 2014, PloS one.

Replication stress activates DNA polymerase alpha-associated Chk1

F. Shanahan, D. Parry, L. Taricani, 2009, Cell cycle.

Cyclin E Associates with BAF155 and BRG1, Components of the Mammalian SWI-SNF Complex, and Alters the Ability of BRG1 To Induce Growth Arrest

E. Lees, W. Seghezzi, F. Shanahan, 1999, Molecular and Cellular Biology.

Effects of Selective Checkpoint Kinase 1 Inhibition on Cytarabine Cytotoxicity in Acute Myelogenous Leukemia Cells In Vitro

Erin L. Schenk, K. Flatten, B. Smith, 2012, Clinical Cancer Research.

Cancer Therapy : Preclinical Effects of Selective Checkpoint Kinase 1 Inhibition on Cytarabine Cytotoxicity in Acute Myelogenous Leukemia Cells In Vitro

Erin L. Schenk, K. Flatten, B. Smith, 2012 .

Pyrazolo[1,5-a]pyrimidines as orally available inhibitors of cyclin-dependent kinase 2.

Brian McKittrick, Yaolin Wang, Emma Lees, 2007, Bioorganic & medicinal chemistry letters.

Discovery of pyrazolo[1,5-a]pyrimidine-based CHK1 inhibitors: a template-based approach--part 2.

T. Fischmann, W. Seghezzi, D. Parry, 2011, Bioorganic & medicinal chemistry letters.

Lack of cyclin D‐Cdk complexes in Rb‐negative cells correlates with high levels of p16INK4/MTS1 tumour suppressor gene product.

G. Peters, S. Bates, D. Mann, 1995, The EMBO journal.

CDK6 (PLSTIRE) and CDK4 (PSK-J3) are a distinct subset of the cyclin-dependent kinases that associate with cyclin D1.

L. Bonetta, G. Peters, S. Bates, 1994, Oncogene.

The identification of novel 5'-amino gemcitabine analogs as potent RRM1 inhibitors.

D. Wyss, W. Seghezzi, F. Shanahan, 2014, Bioorganic & medicinal chemistry.

Regulation of p16CDKN2 expression and its implications for cell immortalization and senescence

G. Peters, E. Hara, D. Parry, 1996, Molecular and cellular biology.

Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumors.

A. Venook, P. Munster, A. Daud, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Targeting the Replication Checkpoint Using SCH 900776, a Potent and Functionally Selective CHK1 Inhibitor Identified via High Content Screening

W. Seghezzi, F. Shanahan, Ming Liu, 2011, Molecular Cancer Therapeutics.

INK4a‐deficient human diploid fibroblasts are resistant to RAS‐induced senescence

G. Peters, K. Vousden, S. Bates, 2002, The EMBO journal.

Complex structure and regulation of the P16 (MTS1) locus.

S. Tavtigian, H. Katcher, G. Peters, 1995, Cancer research.

Deletion and altered regulation of p16INK4a and p15INK4b in undifferentiated mouse skin tumors.

A. Balmain, G. Peters, D. Quelle, 1995, Cancer research.

p14ARF is a component of the p53 response following ionizing irradiation of normal human fibroblasts

David Parry, Shireen Khan, D. Parry, 2004, Oncogene.

Preclinical Development of the Novel Chk1 Inhibitor SCH900776 in Combination with DNA-Damaging Agents and Antimetabolites

A. Eastman, D. Parry, R. Montano, 2011, Molecular Cancer Therapeutics.

Intra-S-Phase Checkpoint Activation by Direct CDK2 Inhibition

E. Lees, D. Parry, R. Doll, 2004, Molecular and Cellular Biology.

Stat3-Dependent Induction of p19INK4D by IL-10 Contributes to Inhibition of Macrophage Proliferation1

F. Zindy, M. Roussel, E. Lees, 2000, The Journal of Immunology.

Macrophage Proliferation IL-10 Contributes to Inhibition of byINK 4 DStat 3-Dependent Induction of p 19

F. Zindy, M. Roussel, E. Lees, 2000 .

Preclinical Development Preclinical Development of the Novel Chk 1 Inhibitor SCH 900776 in Combination with DNA-Damaging Agents and Antimetabolites

A. Eastman, D. Parry, R. Montano, 2012 .

Design, synthesis and SAR of thienopyridines as potent CHK1 inhibitors.

David Parry, T. Fischmann, W. Seghezzi, 2010, Bioorganic & medicinal chemistry letters.

Modulating the interaction between CDK2 and cyclin A with a quinoline-based inhibitor.

Patrick J. Curran, E. Lees, T. Fischmann, 2013, Bioorganic & medicinal chemistry letters.

Structure-guided discovery of cyclin-dependent kinase inhibitors.

Emma Lees, David Parry, Kamil Paruch, 2008, Biopolymers.

Structure-based design and optimization of 2-aminothiazole-4-carboxamide as a new class of CHK1 inhibitors.

Gerald W. Shipps, T. Fischmann, W. Seghezzi, 2013, Bioorganic & medicinal chemistry letters.

In vitro and in vivo characterization of SCH727965 a novel potent cyclin dependent kinase inhibitor

E. Lees, P. Kirschmeier, Yaolin Wang, 2007 .

SCH 727965, a novel cyclin-dependent kinase inhibitor, has potent anti-tumor acitivity in a wide-spectrum of human tumor xenograft models

Lingling Wu, D. Hicklin, E. Lees, 2008 .

Abstract #2490: Targeting the replication checkpoint with a potent and selective CHK1 inhibitor

R. Pierce, W. Seghezzi, F. Shanahan, 2009 .

Discovery of pyrazolo[1,5-a]pyrimidine-based CHK1 inhibitors: a template-based approach--part 2.

T. Fischmann, W. Seghezzi, D. Parry, 2011, Bioorganic & medicinal chemistry letters.